1. Home
  2. REGCP vs BCTXL Comparison

REGCP vs BCTXL Comparison

Compare REGCP & BCTXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Regency Centers Corporation

REGCP

Regency Centers Corporation

HOLD

Current Price

$23.00

Market Cap

0.0

Sector

N/A

ML Signal

HOLD

Logo BriaCell Therapeutics Corp. Warrant expiring 2031

BCTXL

BriaCell Therapeutics Corp. Warrant expiring 2031

N/A

Current Price

$0.70

Market Cap

0.0

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
REGCP
BCTXL
Founded
N/A
N/A
Country
United States
Canada
Employees
507
4
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
N/A
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
REGCP
BCTXL
Price
$23.00
$0.70
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
6.1K
25.3K
Earning Date
N/A
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.35
$0.69
52 Week High
$24.74
$1.40

Technical Indicators

Market Signals
Indicator
REGCP
BCTXL
Relative Strength Index (RSI) 44.84 32.57
Support Level $22.35 N/A
Resistance Level $23.55 $1.25
Average True Range (ATR) 0.18 0.08
MACD -0.04 -0.03
Stochastic Oscillator 30.00 1.32

Price Performance

Historical Comparison
REGCP
BCTXL

About REGCP Regency Centers Corporation

Regency Centers is one of the largest shopping center-focused retail REITs. The company's portfolio includes an interest in 481 properties, which includes over 58 million square feet of retail space following the completion of the Urstadt Biddle acquisition in August 2023. The portfolio is geographically diversified with 22 regional offices and no single market representing more than 12% of total company net operating income. Regency's retail portfolio is primarily composed of grocery-anchored centers, with 80% of properties featuring a grocery anchor and grocery stores representing 20% of annual base rent.

About BCTXL BriaCell Therapeutics Corp. Warrant expiring 2031

BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.

Share on Social Networks: